Pluta Piotr, Giza Agnieszka, Kolenda Małgorzata, Fendler Wojciech, Braun Marcin, Chudobiński Cezary, Chałubińska-Fendler Justyna, Araszkiewicz Michał, Loga Karolina, Lembas Lubomir, Witkowska Magdalena, Pluta Agnieszka, Kolasiński Jerzy, Basta Paweł, Kołacińska-Voytkuv Agnieszka, Cieśla Sławomir, Jesionek-Kupnicka Dorota, Jankau Jerzy, Kuczyński Maciej, Kalinka Ewa, Zadrożny Marek, Murawa Dawid
Department of Surgical Oncology and Breast Diseases, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
Department of Hematology, Jagiellonian University Medical College, Krakow, Poland.
Arch Med Sci. 2020 Nov 5;19(5):1243-1251. doi: 10.5114/aoms.2020.100637. eCollection 2023.
Although breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is infrequent, with less than 1000 noted cases worldwide, patients consenting for breast implant surgery should be aware of its risk. We describe the first Polish multicenter case-series data on BIA-ALCL patients and present diagnostic and treatment recommendation for breast surgeons.
In cooperation with the Polish Society of Surgical Oncology and Polish Lymphoma Research Group, we collected BIA-ALCL cases in Poland.
We retrospectively reviewed clinical data of seven BIA-ALCL patients, diagnosed between July 2013 and November 2019. The median time from implant placement to the first BIA-ALCL symptoms was 65 months (range: 33-96 months). All the patients were exposed to textured implants at presentation. Capsulectomy with implant removal was performed in all the patients with immediate reimplantation in 2 cases. In a median follow-up of 19 months (range 5-81 months), there was no recurrence and all the patients stayed alive. Between 2013 and 2019, the incidence of BIA-ALCL in Polish female population age 30 and above ranged from 0 to 0.021/100 000/year.
BIA-ALCL is scarce in the Polish population. In a short-term follow-up, patients' prognosis remains excellent. Due to the withdrawal of roughly textured implants from the market and the exclusion of likely the most potent etiologic factor, it might be expected that the incidence of BIA-ALCL will become even rarer.
尽管乳房植入物相关间变性大细胞淋巴瘤（BIA-ALCL）并不常见，全球报告病例不足1000例，但同意接受乳房植入手术的患者应了解其风险。我们描述了波兰首个关于BIA-ALCL患者的多中心病例系列数据，并为乳腺外科医生提供诊断和治疗建议。
我们与波兰外科肿瘤学会和波兰淋巴瘤研究小组合作，收集了波兰的BIA-ALCL病例。
我们回顾性分析了2013年7月至2019年11月期间确诊的7例BIA-ALCL患者的临床资料。从植入假体到首次出现BIA-ALCL症状的中位时间为65个月（范围：33-96个月）。所有患者就诊时均使用了毛面假体。所有患者均接受了假体包膜切除术并取出假体，2例患者随后立即进行了乳房重建。中位随访19个月（范围5-81个月），无复发，所有患者均存活。2013年至2019年期间，波兰30岁及以上女性人群中BIA-ALCL的发病率为每年0至0.021/10万。
BIA-ALCL在波兰人群中较为罕见。短期随访显示，患者预后良好。由于表面粗糙的乳房植入物已退出市场，可能消除了最主要的病因，预计BIA-ALCL的发病率将变得更加罕见。
